Everolimus Tablets

A drug used alone or with other drugs to treat certain types of breast cancer, kidney cancer, and pancreatic, lung, and gastrointestinal neuroendocrine tumors. It is used under the brand name Afinitor to treat these cancers and to treat a type of benign kidney tumor called renal angiomyolipoma and a type of benign brain tumor called subependymal giant cell astrocytoma in patients who have tuberous sclerosis. Everolimus is also used under the brand name Afinitor Disperz to treat subependymal giant cell astrocytoma and certain types of seizures in patients who have tuberous sclerosis. It is also used under the brand name Zortress to keep the body from rejecting a kidney or liver transplant. Everolimus is also being studied in the treatment of other conditions and types of cancer. It blocks a protein involved in cell division, which may help keep abnormal cells, including cancer cells, from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Everolimus also lowers the body’s immune response. It is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called RAD001.

Everolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the treatment of renal cell cancer and other tumours

Everolimus is approved to treat:

• Breast cancer. It is used in combination with exemestane in postmenopausal women with advanced hormone receptor–positive (HR+) breast cancer that is also HER2 negative (HER2-) and has not gotten better after treatment with letrozole or anastrozole
• Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body).
• Renal cell carcinoma (a type of kidney cancer) that is advanced, in adults who have not gotten better after treatment with sunitinib or sorafenib.
• Subependymal giant cell astrocytoma in adults and children aged 1 year or older who have tuberous sclerosis and are not able to have surgery.